Know Cancer

or
forgot password

Phase II Trial of Bevacizumab in Combination With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly-diagnosed Glioblastoma Multiforme


Phase 2
18 Years
N/A
Open (Enrolling)
Both
Brain and Central Nervous System Tumors

Thank you

Trial Information

Phase II Trial of Bevacizumab in Combination With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly-diagnosed Glioblastoma Multiforme


OBJECTIVES:

Primary

- To investigate the safety and tolerability of bevacizumab in combination with
temozolomide and external beam fractionated regional radiotherapy as first-line
treatment in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
(Pilot phase)

- To estimate the overall survival of patients treated with this regimen. (Expansion
phase)

Secondary

- To further investigate the safety and tolerability of this regimen in these patients.
(Expansion phase)

- To isolate DNA, RNA, and protein from frozen and paraffin-embedded archival tumor
samples for evaluations, such as immunohistochemical pathway profiling of
VEGF-dependent angiogenic pathways, gene expression microarray, and MGMT promoter
methylation status to define important molecular features of treatment response.

OUTLINE: This is a multicenter study.

Patients undergo external beam fractionated regional radiotherapy once daily 5 days a week
for 6 weeks and receive concurrent oral temozolomide once daily for 6 weeks. Patients also
receive bevacizumab IV over 30-90 minutes every 2 weeks beginning on the first day of
radiotherapy and continuing in the absence of disease progression or unacceptable toxicity.
Beginning 2-5 weeks after completion of radiotherapy, patients receive oral temozolomide on
days 1-5. Treatment with temozolomide repeats every 28 days for up to 24 courses in the
absence of disease progression or unacceptable toxicity.

Blood and frozen and paraffin-embedded tumor tissue samples are collected for biomarker and
genetic analysis.

After completion of study treatment, patients are followed up periodically.


Inclusion Criteria:



- Histologically confirmed intracranial glioblastoma multiforme (GBM) or gliosarcoma.

- Prior histologic diagnosis of low-grade glioma allowed provided it has been upgraded
to GBM after repeat resection

- Has undergone surgery to collect tumor tissue 3-6 weeks ago

- Measurable or assessable disease is not required

- Karnofsky performance status 60-100%

- Life expectancy > 8 weeks

- WBC ≥ 3,000/mm³

- ANC ≥ 1,500/mm³

- Platelet count ≥ 100,000/mm³

- Hemoglobin ≥ 10 g/dL (transfusion allowed)

- SGOT < 2.5 times upper limit of normal (ULN)

- Bilirubin < 2.5 times ULN

- INR ≤ 1.5 times ULN (except if on therapeutic anticoagulation therapy)

- aPTT ≤ 1.5 times ULN (except if on therapeutic anticoagulation therapy)

- Creatinine < 1.5 mg/dL

- Urine protein:creatinine ratio < 1.0

- Negative pregnancy test

- Fertile patients must use effective contraception

- More than 28 days since prior major surgical procedures or open biopsy (other than
craniotomy)

- More than 7 days since prior minor surgical procedures (e.g., placement of PortoCath,
stereotactic biopsy, fine-needle aspirations, or core biopsies)

- More than 4 weeks since prior and no concurrent participation in another experimental
drug study.

- Prior or concurrent corticosteroids, anti-epileptic drugs, analgesics, or other drugs
to treat symptoms or prevent complications are allowed

- Concurrent full-dose warfarin or its equivalent (i.e., unfractionated and/or low
molecular weight heparin) allowed

Exclusion Criteria:

- unstable angina

- BP > 150/100 mm Hg

- NYHA class II-IV congestive heart failure

- myocardial infarction within the past 6 months

- stroke within the past 6 months

- clinically significant peripheral vascular disease

- evidence of bleeding diathesis or coagulopathy

- intracerebral abscess within past 6 months

- abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within
the past 6 months

- serious, non-healing wound, ulcer, or bone fracture

- Any wound requiring surgical intervention (including scalp wounds requiring
cranioplasty) allowed provided the wound is clean and without further infection
post-surgical intervention

- significant traumatic injury within the past 28 days

- concurrent serious uncontrolled medical illness including, but not limited to, the
following:

- Ongoing or active infection requiring IV antibiotics

- Psychiatric illness/social situation that would limit compliance with study
requirements

- Disorders associated with significant immunocompromised state (e.g., HIV, systemic
lupus erythematosus)

- other cancer within the past 3 years, except nonmelanoma skin cancer or carcinoma in
situ of the cervix

- disease that would obscure toxicity or dangerously alter drug metabolism

- significant medical illness that, in the investigator's opinion, cannot be adequately
controlled with appropriate therapy or would compromise the patient's ability to
tolerate study therapy

- prior radiotherapy to the brain

- prior cytotoxic or non-cytotoxic drug therapy or experimental drug therapy for the
brain tumor

- prior Gliadel wafers

- concurrent participation in any other clinical trial

- concurrent GM-CSF

- concurrent stereotactic radiosurgery or brachytherapy

- concurrent major surgical procedure

- other concurrent anticancer therapy, including chemotherapy, hormonal therapy,
radiotherapy, or immunotherapy

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Overall survival

Safety Issue:

No

Principal Investigator

Albert Lai, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Ronald Reagan UCLA Medical Center

Authority:

United States: Food and Drug Administration

Study ID:

CDR0000628787

NCT ID:

NCT01013285

Start Date:

June 2006

Completion Date:

Related Keywords:

  • Brain and Central Nervous System Tumors
  • adult giant cell glioblastoma
  • adult gliosarcoma
  • adult glioblastoma
  • Glioblastoma
  • Nervous System Neoplasms
  • Central Nervous System Neoplasms
  • Gliosarcoma

Name

Location

Jonsson Comprehensive Cancer Center, UCLA Los Angeles, California  90095-1781